-
September 10, 2021ES104 (CTX-009/ABL001) Clinical Data Presented at the 2021 AACR-NCI-EORTC International Conference
1. ES104 was well tolerated and demonstrated single agent activity in heavily pre-treated patients with solid tumor who are resistant to anti-VEGF therapies, mostly of colorectal and gastric orig...
-
September 10, 2021Elpiscience Announces FDA Approval of IND Application for ES002 (anti-CD39 mAb)
Shanghai/Suzhou/Maryland, September 10, 2021. Elpiscience Biopharmaceuticals, Inc. (“Elpiscience”), a global clinical-stage biopharmaceutical company focusing on discovering and devel...
-
June 25, 2021Elpiscience Announces CDE Clearance of IND Application for ES102 in Combination of Toripalimab
SHANGHAI/SUZHOU, China, June 25, 2021. Elpiscience Biopharma Ltd., a clinical-stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, today announced...
-
June 02, 2021Elpiscience to Present at the Jefferies 2021 Healthcare Conference
SHANGHAI/SUZHOU, China, June 2, 2021. Elpiscience Biopharma Ltd., a clinical stage biotech company focusing on the discovery and development of next-generation cancer immunotherapies, today announced ...
-
May 13, 2021Elpiscience Announces the Completion of $105 Million Series C Financing
SHANGHAI/SUZHOU, China, May 13, 2021. Elpiscience Biopharma, a clinical stage biopharma focusing on the discovery and development of next-generation cancer immunotherapies, announced today the cl...
-
January 20, 2021Elpiscience and TRIGR Announce an Exclusive License Agreement of TR009 in Greater China
1. Transaction to immediately accelerate clinical development of TR009 in Greater China and combine with Elpiscience’s deep pipeline of next generation immunotherapies； 2. TRIGR and Elpiscien...